Statement: There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 5/33 (15.15%)   Left Ventricular Thrombus * 1/33 (3.03%)   Nausea * 1/33 (3.03%)   Acute Cholecystitis * 1/33 (3.03%)   Renal Failure * 1/33 (3.03%)   Pneumonia * 1/33 (3.03%)
Secondary_evidence: Adverse Events 1:   Total: 14/76 (18.42%)   Neutropenia 10/76 (13.16%)   Febrile neutropenia 1/76 (1.32%)   Anaemia 0/76 (0.00%)   Thrombocytopenia 0/76 (0.00%)   Cardiopulmonary failure 0/76 (0.00%)   Optic ischaemic neuropathy 0/76 (0.00%)   Bowel peristalsis increased 1/76 (1.32%)   Colitis 0/76 (0.00%)   Diarrhoea 0/76 (0.00%)   Gastritis 0/76 (0.00%)   Nausea 0/76 (0.00%) Adverse Events 2:   Total: 12/76 (15.79%)   Neutropenia 2/76 (2.63%)   Febrile neutropenia 1/76 (1.32%)   Anaemia 0/76 (0.00%)   Thrombocytopenia 0/76 (0.00%)   Cardiopulmonary failure 1/76 (1.32%)   Optic ischaemic neuropathy 1/76 (1.32%)   Bowel peristalsis increased 0/76 (0.00%)   Colitis 1/76 (1.32%)   Diarrhoea 0/76 (0.00%)   Gastritis 0/76 (0.00%)   Nausea 1/76 (1.32%)